Oral amphipathic peptides as therapeutic agents. 2006

Srinivasa T Reddy, and G M Anantharamaiah, and Mohamad Navab, and Susan Hama, and Gregory Hough, and Victor Grijalva, and David W Garber, and Geeta Datta, and Alan M Fogelman
Division of Cardiology, Department of Medicine, David Geffen School of Medicine, UCLA, Los Angeles, California 90095-1679, USA. SReddy@mednet.ucla.edu

Cholesterol can promote inflammation by its ability to stimulate the production of reactive oxygen species that result in the formation of pro-inflammatory oxidised phospholipids. High-density lipoproteins (HDLs) are part of the innate immune response and can be either pro- or anti-inflammatory independently of plasma HDL-cholesterol levels. During systemic inflammation as occurs with atherosclerosis, Apolipoprotein A-I can be altered, reducing its ability to promote reverse cholesterol transport and HDL can become pro-inflammatory. Amphipathic peptides with either a class A amphipathic helix (D-4F) or a class G* amphipathic helix (D-[113-122]apoJ), or even those that are too small to form a helix (KRES and FREL) have some similar characteristics. Their interaction with lipids leads to a reduction in lipoprotein-lipid hydroperoxides that releases HDL-associated antioxidant enzymes, such as paraoxonase, therefore providing antiatherosclerosis and anti-inflammatory activity. In addition, the peptide D-4F stimulates the formation and cycling of pre-beta HDL. These amphipathic peptides appear to have therapeutic potential as oral agents.

UI MeSH Term Description Entries
D007113 Immunity, Innate The capacity of a normal organism to remain unaffected by microorganisms and their toxins. It results from the presence of naturally occurring ANTI-INFECTIVE AGENTS, constitutional factors such as BODY TEMPERATURE and immediate acting immune cells such as NATURAL KILLER CELLS. Immunity, Native,Immunity, Natural,Immunity, Non-Specific,Resistance, Natural,Innate Immune Response,Innate Immunity,Immune Response, Innate,Immune Responses, Innate,Immunity, Non Specific,Innate Immune Responses,Native Immunity,Natural Immunity,Natural Resistance,Non-Specific Immunity
D007249 Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function. Innate Inflammatory Response,Inflammations,Inflammatory Response, Innate,Innate Inflammatory Responses
D008075 Lipoproteins, HDL A class of lipoproteins of small size (4-13 nm) and dense (greater than 1.063 g/ml) particles. HDL lipoproteins, synthesized in the liver without a lipid core, accumulate cholesterol esters from peripheral tissues and transport them to the liver for re-utilization or elimination from the body (the reverse cholesterol transport). Their major protein component is APOLIPOPROTEIN A-I. HDL also shuttle APOLIPOPROTEINS C and APOLIPOPROTEINS E to and from triglyceride-rich lipoproteins during their catabolism. HDL plasma level has been inversely correlated with the risk of cardiovascular diseases. High Density Lipoprotein,High-Density Lipoprotein,High-Density Lipoproteins,alpha-Lipoprotein,alpha-Lipoproteins,Heavy Lipoproteins,alpha-1 Lipoprotein,Density Lipoprotein, High,HDL Lipoproteins,High Density Lipoproteins,Lipoprotein, High Density,Lipoprotein, High-Density,Lipoproteins, Heavy,Lipoproteins, High-Density,alpha Lipoprotein,alpha Lipoproteins
D010455 Peptides Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are considered to be larger versions of peptides that can form into complex structures such as ENZYMES and RECEPTORS. Peptide,Polypeptide,Polypeptides
D002784 Cholesterol The principal sterol of all higher animals, distributed in body tissues, especially the brain and spinal cord, and in animal fats and oils. Epicholesterol
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D004353 Drug Evaluation, Preclinical Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications. Drug Screening,Evaluation Studies, Drug, Pre-Clinical,Drug Evaluation Studies, Preclinical,Drug Evaluations, Preclinical,Evaluation Studies, Drug, Preclinical,Evaluation, Preclinical Drug,Evaluations, Preclinical Drug,Medicinal Plants Testing, Preclinical,Preclinical Drug Evaluation,Preclinical Drug Evaluations,Drug Screenings,Screening, Drug,Screenings, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

Srinivasa T Reddy, and G M Anantharamaiah, and Mohamad Navab, and Susan Hama, and Gregory Hough, and Victor Grijalva, and David W Garber, and Geeta Datta, and Alan M Fogelman
January 2020, Frontiers in cellular and infection microbiology,
Srinivasa T Reddy, and G M Anantharamaiah, and Mohamad Navab, and Susan Hama, and Gregory Hough, and Victor Grijalva, and David W Garber, and Geeta Datta, and Alan M Fogelman
January 2012, International journal of microbiology,
Srinivasa T Reddy, and G M Anantharamaiah, and Mohamad Navab, and Susan Hama, and Gregory Hough, and Victor Grijalva, and David W Garber, and Geeta Datta, and Alan M Fogelman
January 2022, Methods in molecular biology (Clifton, N.J.),
Srinivasa T Reddy, and G M Anantharamaiah, and Mohamad Navab, and Susan Hama, and Gregory Hough, and Victor Grijalva, and David W Garber, and Geeta Datta, and Alan M Fogelman
January 1993, Clinical and experimental rheumatology,
Srinivasa T Reddy, and G M Anantharamaiah, and Mohamad Navab, and Susan Hama, and Gregory Hough, and Victor Grijalva, and David W Garber, and Geeta Datta, and Alan M Fogelman
February 2021, Journal of microbiology (Seoul, Korea),
Srinivasa T Reddy, and G M Anantharamaiah, and Mohamad Navab, and Susan Hama, and Gregory Hough, and Victor Grijalva, and David W Garber, and Geeta Datta, and Alan M Fogelman
January 2017, International journal of medical sciences,
Srinivasa T Reddy, and G M Anantharamaiah, and Mohamad Navab, and Susan Hama, and Gregory Hough, and Victor Grijalva, and David W Garber, and Geeta Datta, and Alan M Fogelman
August 2016, Chemical record (New York, N.Y.),
Srinivasa T Reddy, and G M Anantharamaiah, and Mohamad Navab, and Susan Hama, and Gregory Hough, and Victor Grijalva, and David W Garber, and Geeta Datta, and Alan M Fogelman
September 2018, International journal of molecular sciences,
Srinivasa T Reddy, and G M Anantharamaiah, and Mohamad Navab, and Susan Hama, and Gregory Hough, and Victor Grijalva, and David W Garber, and Geeta Datta, and Alan M Fogelman
January 2012, Biomolecules & therapeutics,
Srinivasa T Reddy, and G M Anantharamaiah, and Mohamad Navab, and Susan Hama, and Gregory Hough, and Victor Grijalva, and David W Garber, and Geeta Datta, and Alan M Fogelman
November 2020, Critical reviews in biotechnology,
Copied contents to your clipboard!